ResMed’s strong demand for AirSense 11 boosts its earnings outlook. Learn why RMD stock is undervalued with growth ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

Medical device company ResMed (NYSE:RMD) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on ...

ResMed’s competitive edge is strong, but its current valuation seems inflated. Read why RMD stock might be ripe for ...

The US-based Australian sleep apnoea device giant has exceeded expectations with strong second quarter numbers.

Year-over-year revenue grows 10%, operating profit up 52%, non-GAAP operating profit up 19%Operating cash flow of $309 millionNote: A webcast of ...

The great quarter was driven by high demand for sleep-related products and growth in digital health solutions. As a specialist in sleep and respiratory health, ResMed built its reputation through ...

Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...

ResMed has beaten its earnings forecast in the second quarter despite concerns from investors around weight loss drugs ...

Rating on Tuesday, with an increase from 68 to 72. Please watch the video at Investors.com - Do Your Stocks Meet This Key ...

ResMed’s (ASX:RMD) half-year FY25 results reflect a company that is not only thriving in its core business but is also ...

Passive income investors looking to grab the record-high ResMed Inc (ASX: RMD) dividend will need to act soon. Here’s what’s ...